Interfacial profiles in the rough phase.
Explore the source record for details and available documents.
Journal Article↗
Biomedical subjects
A Kooiman
Publications and source records attributed to A Kooiman.
Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian Cancer.
In 23 evaluable patients with advanced ovarian epithelial cancer refractory to combination therapy with cisplatin and an alkylating agent, teniposide (VM-26) was administered as a short-term i.v. infusion at a dose of 100 mg/m2 on days 1 and 2, every 3 weeks. Toxicity was moderate and comparable to the pattern known from other studies. No objective response has been observed, showing that teniposide is not active as second-line therapy in this disease.
Antineoplastic Combined Chemotherapy Protocols↗